Progress in the delivery of therapeutic oligonucleotides: Organ/cellular distribution and targeted delivery of oligonucleotides in vivo

Antisense and Nucleic Acid Drug Development

Volumn 13, Issue 3, 2003, Pages 169-189

  Wang, Laixin ^a   Prakash, Ramesh K ^a   Stein, C A ^b   Koehn, Richard K ^a   Ruffner, Duane E ^a  

^a Salus Therapeutics   (United States)

^b ALBERT EINSTEIN CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; ANTISENSE OLIGONUCLEOTIDE; EPI 2010; GM 231; ISIS 1082; ISIS 11159; ISIS 14725; ISIS 16952; ISIS 18268; ISIS 22023; ISIS 9044; OBLIMERSEN; PHOSPHOROTHIOATE OLIGONUCLEOTIDE; UNCLASSIFIED DRUG; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; OLIGONUCLEOTIDE;

ANIMAL CELL; CELLULAR DISTRIBUTION; DRUG DELIVERY SYSTEM; DRUG METABOLISM; DRUG TARGETING; DRUG UPTAKE; NONHUMAN; ORGAN DISTRIBUTION; PRIORITY JOURNAL; RAT; REVIEW; DRUG EFFICACY; IN VIVO STUDY; KIDNEY; LIVER; PLASMA CLEARANCE;

ANIMALIA;

EID: 24144463114     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729003768247637     Document Type: Review

References (118)

1. AGRAWAL, S. (1999). Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochem. Biophys. Acta 1489, 53-68.
2. AGRAWAL, S., TEMSAMANI, J., GALBRAITH, W., and TANG, J. (1995a). Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet. 28, 7-16.
3. AGRAWAL, S., and ZHANG, R. (1998). Pharmacokinetics and bioavailability of oligonucleotides following oral and colorectal administration in experimental animals. In: Antisense Research and Application: Handbook of Experimental Pharmacology. S.T. Crooke, ed. (Springer, Berlin), pp. 525-543.
4. AGRAWAL, S., ZHANG, X., LU, Z., ZHAO, H., TAMBURIN, J.M., YAN, J., CAI, H., DIASIO, R.B., HABUS, I., JIANG, Z., et al. (1995b). Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem. Pharmacol. 50, 571-576.
5. ALI, S., LEONARD, S.A., KUKOLY, C.A., METZGER, W.J., WOOLES, W.R., McGINTY, J.F., TANAKA, M., SANDRA-SAGRA, A., and NYCE, J.W. (2001). Absorption, distribution, metabolism, and excretion of a respirable antisense oligonucleotide for asthma. Am. J. Respir. Crit. Care Med. 163, 989-993.
6. AOKI, Y., HOSAKA, S., KAWA, S., and KIYOSAWA, K. (2001). Potential tumor-targeting peptide vector of histidylated oligolysine conjugated to a tumor-homing RGD motif. Cancer Gene Ther. 8, 783-787.
7. ARAP, W., PASQUALINI, R., and RUOSLAHTI, E. (1998). Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279, 377-380.
8. ASHWELL, G., and HARFORD, J. (1982). Carbohydrate-specific receptors of the liver. Annu. Rev. Biochem. 51, 531-554.
9. BACHMANN, A.S., SUROVOY, A., JUNG, G., and MOELLING, K. (1998). Integrin receptor-targeted transfer peptides for efficient delivery of antisense oligodeoxynucleotides. J. Mol. Med. 76, 126-132.
10. BARTHOLOMEW, R.M., CARMICHAEL, E.P., FINDEIS, M.A., WU, C.H., and WU, G.Y. (1995). Targeted delivery of antisense DNA in woodchuck hepatitis virus-infected woodchucks. J. Viral Hepat. 2, 273-278.
11. BENIMETSKAYA, L., TONKINSON, J.L., KOZIOLKIEWICZ, M., KARWOWSKI, B., GUGA, P., ZELTSER, R., STEC, W., and STEIN, C.A. (1995). Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P-chirality independent. Nucleic Acids Res. 23, 4239-4245.
12. BENNETT, R.M., GABOR, G.T., and MERRITT, M.M. (1985). DNA binding to human leukocytes. Evidence for a receptor-mediated association, internalization, and degradation of DNA. J. Clin. Invest. 76, 2182-2190.
13. BENNS, J.M., MAHATO, R.I., and KIM, S.W. (2002). Optimization of factors influencing the transfection efficiency of folate-PEG-folate-graft-polyethylenimine. J. Control Release 79, 255-269.
14. BENNS, J.M., MAHESHWARI, A., FURGESON, D.Y., MAHATO, R.I., and KIM, S.W. (2001). Folate-PEG-folate-graft-polyethylenimine-based gene delivery. J. Drug Target 9, 123-139.
15. BIESSEN, E.A., SLIEDREGT-BOL, K., PA, T.H., PRINCE, P., VAN DER BILT, E., VALENTIJN, A.R., MEEUWENOORD, N.J., PRINCEN, H., BIJSTERBOSCH, M.K., VAN DER MAREL, G.A., VAN BOOM, J.H., and VAN BERKEL, T.J. (2002). Design of a targeted peptide nucleic acid prodrug to inhibit hepatic human microsomal triglyceride transfer protein expression in hepatocytes. Bioconjug. Chem. 13, 295-302.
16. BIESSEN, E.A., VIETSCH, H., RUMP, E.T., FLUITER, K., KUIPER, J., BIJSTERBOSCH, M.K., and VAN BERKEL, T.J. (1999). Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo. Biochem. J. 340, 783-792.
17. BIJSTERBOSCH, M.K., MANOHARAN, M., RUMP, E.T., DE VRUEH, R.L., VAN VEGHEL, R., TIVEL, K.L., BIESSEN, E.A., BENNETT, C.F., COOK, P.D., and VAN BERKEL, T.J. (1997). In vivo fate of phosphorothioate antisense oligodeoxynucleotides: Predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res. 25, 3290-3296.
18. BRAND, R.M., HANNAH, T.L., NORRIS, J., and IVERSEN, P.L. (2001). Transdermal delivery of antisense oligonucleotides can induce changes in gene expression in vivo. Antisense Nucleic Acid Drug Dev. 11, 1-6.
19. BRAND, R.M., and IVERSEN, P.L. (2000). Transdermal delivery of antisense compounds. Adv. Drug Deliv. Rev. 44, 51-57.
20. BROWN, D.A., KANG, S.H., GRYAZNOV, S.M., DEDIONISIO, L., HEIDENREICH, O., SULLIVAN, S., XU, X., and NERENBERG, M.I. (1994). Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J. Biol. Chem. 269, 26801-26805.
21. BUTLER, M., CROOKE, R.M., GRAHAM, M.J., LEMONIDIS, K.M., LOUGHEED, M., MURRAY, S.F., WITCHELL, D., STEINBRECHER, U., and BENNETT, C.F. (2000). Phosphorothioate oligodeoxynucleotides distribute similarly in class A scavenger receptor knockout and wild-type mice. J. Pharmacol. Exp. Ther. 292, 489-496.
22. BUTLER, M., STECKER, K., and BENNETT, C.F. (1997). Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab. Invest. 77, 379-388.
23. CARMICHAEL, E., CHIOU, H., FINDEIS, M., SPITALNY, G., and MERWIN, J. (1995). Targeted delivery of anti-hepatitis B oligonucleotides. In: Delivery Strategies for Antisense Oligonucleotide Therapeutics. S. Akhtar, ed. (CRC Press, New York), pp. 267-282.
24. CITRO, G., SZCZYLIK, C., GINOBBI, P., ZUPI, G., and CALABRETTA, B. (1994). Inhibition of leukaemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligodeoxynucleotides into HL-60 cells. Br. J. Cancer 69, 463-467.
25. COLIN, M., HARBOTTLE, R.P., KNIGHT, A., KORNPROBST, M., COOPER, R.G., MILLER, A.D., TRUGNAN, G., CAPEAU, J., COUTELLE, C., and BRAHIMI-HORN, M.C. (1998). Liposomes enhance delivery and expression of an RGD-oligolysine gene transfer vector in human tracheal cells. Gene Ther. 5, 1488-1498.
26. COOK, P.D. (2001). Medicinal chemistry of antisense oligonucleotides. In: Antisense Drug Technology: Principles, strategies and applications. S.T. Crooke, ed. (Marcel Dekker, New York), pp. 29-55.
27. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after in travenous administration to rats. J. Pharmacol. Exp. Ther. 267, 1181-1190.
28. 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J. Pharmacol. Exp. Ther. 269, 89-94.
29. CROOKE, R.M., and GRAHAM, M.J. (2001). Suborgan pharmacokinetics. In: Antisense Drug Technology: Principles, Strategies and Applications. S.T. Crooke, ed. (Marcel Dekker, New York), pp. 155-182.
30. CROOKE, R.M., GRAHAM, M.J., COOKE, M.E., and CROOKE, S.T. (1995). In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. J. Pharmacol. Exp. Ther. 275, 462-473.
31. CROOKE, R.M., GRAHAM, M.J., MARTIN, M.J., LEMONIDIS, K.M., WYRZYKIEWIECZ, T., and CUMMINS, L.L. (2000). Metabolism of antisense oligonucleotides in rat liver homogenates. J. Pharmcol. Exp. Ther. 292, 140-149.
32. CROOKE, S.T. (2000). Potential roles of antisense technology in cancer chemotherapy. Oncogene 19, 6651-6659.
33. CROOKE, S.T., GRAHAM, M.J., ZUCKERMAN, J.E., BROOKS, D., CONKLIN, B.S., CUMMINS, L.L., GREIG, M.J., GUINOSSO, C.J., KORNBRUST, D., MANOHARAN, M., SASMOR, H.M., SCHLEICH, T., TIVEL, K.L., and GRIFFEY, R.H. (1996). Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther. 277, 923-937.
34. DEAN, N.M., and GRIFFEY, R.H. (1997). Identification and characterization of second-generation antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 7, 229-233.
35. ELICEIRI, B.P., and CHERESH, D.A. (2000). Role of alpha v integrins during angiogenesis. Cancer J. Sci. Am. 6(Suppl 3), S245-S249.
36. ERBACHER, P., REMY, J.S., and BEHR, J.P. (1999). Gene transfer with synthetic virus-like particles via the integrin-mediated endocytosis pathway. Gene Ther. 6, 138-145.
37. FAMULOK, M., and VERMA, S. (2002). In vivo-applied functional RNAs as tools in proteomics and genomics research. Trends Biotechnol. 20, 462-466.
38. GEARY, R.S., KHATSENKO, O., BUNKER, K., CROOKE, R., MOORE, M., BURCKIN, T., TRUONG, L., SASMOR, H., and LEVIN, A.A. (2001a). Absolute bioavailability of 2′-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. J. Pharmacol. Exp. Ther. 296(3), 898-904.
39. GEARY, R.S., LEEDS, J.M., FITCHETT, J., BURCKIN, T., TRUONG, L., SPAINHOUR, C., CREEK, M., and LEVIN, A.A (1997a). Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab. Dispos. 25, 1272-1281.
40. GEARY, R.S., LEEDS, J.M., HENRY, S.P., MONTEITH, D.K., and LEVIN, A.A. (1997b). Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des. 12, 383-393.
41. GEARY, R.S., WATANABE, T.A., TRUONG, L., FREIER, S., LESNIK, E.A., SIOUFI, N.B., SASMOR, H., MANOHARAN, M., and LEVIN, A.A. (2001b). Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J. Pharmacol. Exp. Ther. 296, 890-897.
42. GEARY, R.S., YU, R.Z., and LEVIN, A.A. (2001c). Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr. Opin. Investig. Drugs 2, 562-573.
43. GESELOWITZ, D.A., and NECKERS, L.M. (1992). Analysis of oligonucleotide binding, internalization, and intracellular trafficking utilizing a novel radiolabeled crosslinker. Antisense Res. Dev. 2, 17-25.
44. GEWIRTZ, A.T., and SITARAMAN, S. (2001). Alicaforsen. Isis Pharmaceuticals. Curr. Opin. Investig. Drugs 2, 1401-1406.
45. GINOBBI, P., GEISER, T.A., OMBRES, D., and CITRO, G. (1997). Folic acid-polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells. Anticancer Res. 17, 29-35.
46. GLOVER, J.M., LEEDS, J.M., MANT, T.G., AMIN, D., KISNER, D.L., ZUCKERMAN, J.E., GEARY, R.S., LEVIN, A.A., and SHANAHAN, W.R., JR. (1997). Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J. Pharmacol. Exp. Ther. 282, 1173-1180.
47. GRAHAM, M.J., CROOKE, S.T., LEMONIDIS, K.M., GAUS, H.J., TEMPLIN, M.V., and CROOKE, R.M. (2001). Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration. Biochem. Pharmacol. 62, 297-306.
48. GRAHAM, M.J., CROOKE, S.T., MONTEITH, D.K., COOPER, S.R., LEMONIDIS, K.M., STECKER, K.K., MARTIN, M.J., and CROOKE, R.M. (1998). In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J. Pharmacol. Exp. Ther. 286(1), 447-458.
49. GRAY, G.D., BASU, S., and WICKSTROM, E. (1997). Transformed and immortalized cellular uptake of oligodeoxynucleoside phosphorothioates, 3′-alkylamino oligodeoxynucleotids, 2′-O-methyl oligoribonucleotides, oligodeoxynucleoside methylphosphonates, and peptide nucleic acids. Biochem. Pharmacol. 53, 1465-1476.
50. GREIG, M., GAUS, H., CUMMINS, L., SASMOR, H., and GRIFFEY, R. (1995). Measurement of macromolecular binding using electrospray mass spectrometry. Determination of diassociation constants for oligonucleotide-serum albumin complexes. J. Am. Chem. Soc. 117, 10765-10766.
51. GUO, W., and LEE, R.L. (1999). Receptor-targeted gene delivery via folate-conjugated polyethylenimine. AAPS Pharm. Sci. 1(4), E19.
52. 32P]-labeled oligodeoxynucleoside methylphosphonate-neoglycopeptide conjugate, [YEE(ah-GalNAc)3]-SMCC-AET-pUmpT7, in the mouse. Antisense Nucleic Acid Drug Dev. 7, 141-149.
53. HARBOTTLE, R.P., COOPER, R.G., HART, S.L., LADHOFF, A., McKAY, T., KNIGHT, A.M., WAGNER, E., MILLER, A.D., and COUTELLE, C. (1998). An RGD-oligolysine peptide: A prototype construct for integrin-mediated gene delivery. Hum. Gene Ther. 9, 1037-1047.
54. HARDEE, G.E., WEINBACH, S.P., and TILLMAN, L.G. (2001). New route and novel formulations for delivery of antisense oligonucleotides. In: Antisense Drug Technology: Principles, Strategies, and Applications. S.T. Crooke, ed. (Marcel Dekker, Inc, New York), pp. 759-832.
55. HENRY, S.P., BOLTE, H., AULETTA, C., and KORNBRUST, D.J. (1997a). Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. Toxicology 120, 145-155.
56. HENRY, S.P., GICLAS, P.C., LEEDS, J., PANGBURN, M., AULETTA, C., LEVIN, A.A., and KORNBRUST, D.J. (1997b). Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action. J. Pharmacol. Exp. Ther. 281, 810-816.
57. HOFLAND, H.E., MASSON, C., IGINLA, S., OSETINSKY, I., REDDY, J.A., LEAMON, C.P., SCHERMAN, D., BESSODES, M., and WILS, P. (2002). Folate-targeted gene transfer in vivo. Mol. Ther. 5, 739-744.
58. HOGREFE, R.I. (1999). An antisense oligonucleotide primer. Antisense Nucleic Acid Drug Dev. 9, 351-357.
59. IVERSON, P.L., CROUSE, D., ZON, G., and PERRY, G. (1992). Binding of antisense phosphorothioate oligonucleotides to murine lymphocytes is lineage specific and inducible. Antisense Res. Dev. 2, 223-233.
60. KITAJIMA, I., SHINOHARA, T., MINOR, T., BIBS, L., BILAKOVICS, J., AND NERENBERG, M. (1992). Human T-cell leukemia virus type I tax transformation is associated with increased uptake of oligodeoxynucleotides in vitro and in vivo. J. Biol. Chem. 267, 25881-25888.
61. KREN, B.T., BANDYOPADHYAY, P., and STEER, C.J. (1998). In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides. Nat. Med. 4, 285-290.
62. LEAMON, C.P., WEIGL, D., and HENDREN, R.W. (1999). Folate copolymer-mediated transfection of cultured cells. Bioconjug. Chem. 10, 947-957.
63. LEE, R.J., and HUANG, L. (1996). Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer. J. Biol. Chem. 271, 8481-8487.
64. LEEDS, J.M., HENRY, S.P., GEARY, R., BURCKIN, T., and LEVIN, A.A. (2000). Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys. Antisense Nucleic Acid Drug Dev. 10, 435-441.
65. LEVIN, A.A. (1999). A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta 1489, 69-84.
66. LITZINGER, D.C. (1997). Limitations of cationic liposomes for antisense oligonucleotide delivery in vivo. J. Liposome Res. 7, 51-56.
67. LOPES, D., and MAYER, L.D. (2002). Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. Cancer Chemother. Pharmacol. 49, 57-68.
68. MAHATO, R.I., KAWABATA, K., NOMURA, T., TAKAKURA, Y., and HASHIDA, M. (1995). Physicochemical and pharmacokinetic characteristics of plasmid DNA/cationic liposome complexes. J. Pharm. Sci. 84, 1267-1271.
69. MAHATO, R.I., TAKEMURA, S., AKAMATSU, K., NISHIKAWA, M., TAKAKURA, Y., and HASHIDA, M. (1997). Physiocochemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly(L-lysine). Biochem. Pharmacol. 53, 887-895.
70. MEHTA, R.C., STECKER, K.K., COOPER, S.R., TEMPLIN, M.V., TSAI, Y.J., CONDON, T.P., BENNETT, C.F., and HARDEE, G.E. (2000). Intercellular adhesion molecule-1 suppression in skin by topical delivery of anti-sense oligonucleotides. J. Invest. Dermatol. 115, 805-812.
71. MONTEITH, D.K., HORNER, M.J., GILLETT, N.A., BUTLER, M., GEARY, R., BURCKIN, T., USHIRO-WATANABE, T., and LEVIN, A.A. (1999). Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys. Toxicol. Pathol. 27, 307-317.
72. MORISHITA, R., YAMADA, S., YAMAMOTO, K., TOMITA, N., KIDA, I., SAKURABAYASHI, I., KIKUCHI, A., KANEDA, Y., LAWN, R., HIGAKI, J., and OGIHARA, T. (1998). Novel therapeutic strategy for atherosclerosis: Ribozyme oligonucleotides against apolipoprotein(a) selectively inhibit apolipoprotein(a) but not plasminogen gene expression. Circulation 98, 1898-1904.
73. NAKAZONO, K., ITO, Y., WU, C.H., and WU, G.Y. (1996). Inhibition of hepatitis B virus replication by targeted pretreatment of complexed antisense DNA in vitro. Hepatology 23, 1297-1303.
74. NEURATH, M.F., PETTERSSON, S., MEYER ZUM BUSCHENFELDE, K.H., and STROBER, W. (1996). Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat. Med. 2, 998-1004.
75. NICKLIN, P.L., BAYLEY, D., GIDDINGS, J., CRAIG, S.J., CUMMINS, L.L., HASTEWELL, J.G., and PHILLIPS, J.A. (1998a). Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): Comparison with other delivery routes. Pharm. Res. 15, 583-591.
76. NICKLIN, P.L., CRAIG, S., and PHILLIPS, J. (1998b). Pharmacokinetic properties of phosphorothioates in animals - Absorption, distribution, metabolism and elimination. In: Antisense Research and Applications. S. Crooke, ed. (Springer-Verlag, Berlin), pp. 141-168.
77. NYCE, J.W., and METZGER, W.J. (1997). DNA antisense therapy for asthma in an animal model. Nature 385, 721-725.
78. OBERBAUER, R., MURER, H., SCHREINER, G.F., and MEYER, T.W. (1996). Antisense and the kidney. Kidney Blood Press. Res. 19, 221-224.
79. OBERBAUER, R., SCHREINER, G.F., and MEYER, T.W. (1995). Renal uptake of an 18-mer phosphorothioate oligonucleotide. Kidney Int. 48, 1226-1232.
80. OCHIETTI, B., GUERIN, N., VINOGRADOV, S.V., ST-PIERRE, Y., LEMIEUX, P., KABANOV, A.V., and ALAKHOV, Y. (2002). Altered organ accumulation of oligonucleotides using polyethyleneimine grafted with poly(ethylene oxide) or pluronic as carrier. J. Drug Target. 10(2), 113-121.
81. OGRIS, M., BRUNNER, S., SCHULLER, S., KIRCHEIS, R., and WAGNER, E. (1999). PEGylated DNA/transferrin-PEI complexes: Reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther. 6, 595-605.
82. OPALINSKA, J.B., and GEWIRTZ, A.M. (2002). Nucleic acid therapeutics: Basic principles and recent applications. Nat. Rev. Drug Discov. 1, 503-514.
83. PASQUALINI, R., KOIVUNEN, E., and RUOSLAHTI, E. (1997). Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol. 15, 542-546.
84. PIERCE, M.L., and RUFFNER, D.E. (1998). Construction of a directed hammerhead ribozyme library: Towards the identification of optimal target sites for antisense-mediated gene inhibition. Nucleic Acids Res. 26, 5093-5101.
85. PLENAT, F., KLEIN-MONHOVEN, N., MARIE, B., VIGNAUD, J.M., and DUPREZ, A. (1995). Cell and tissue distribution of synthetic oligonucleotides in healthy and tumor-bearing nude mice. An autoradiographic, immunohistological, and direct fluorescence microscopy study. Am. J. Pathol. 147, 124-135.
86. PONNAPPA, B., DEY, I., TU, G.-C., ZHOU, F., CAO, Q.-N., and ISRAEL, Y. (1998). In vivo delivery of antisense oligonucleotides into rat Kupffer cells. J. Lipsome Res. 8, 521-535.
87. PONNAPPA, B.C., DEY, I., TU, G.C., ZHOU, F., AINI, M., CAO, Q.N., and ISRAEL, Y. (2001). In vivo delivery of antisense oligonucleotides in pH-sensitive liposomes inhibits lipopolysaccharide-induced production of tumor necrosis factor-alpha in rats. J. Pharmacol. Exp. Ther. 297, 1129-1136.
88. REDDY, J.A., DEAN, D., KENNEDY, M.D., and LOW, P.S. (1999). Optimization of folate-conjugated liposomal vectors for folate receptor-mediated gene therapy. J. Pharm. Sci. 88, 1112-1118.
89. RICHARDSON, P.D., KREN, B.T., and STEER, C.J. (2002). Gene repair in the new age of gene therapy. Hepatology 35, 512-518.
90. RIFAI, A., BRYSCH, W., FADDEN, K., CLARK, J., and SCHLINGENSIEPEN, K.H. (1996). Clearance kinetics, biodistribution, and organ saturability of phosphorothioate oligodeoxynucleotides in mice. Am. J. Pathol. 149, 717-725.
91. 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol. Pharmacol. 45, 932-943.
92. SATO, N., KOBAYASHI, H., SAGA, T., NAKAMOTO, Y., ISHIMORI, T., TOGASHI, K., FUJIBAYASHI, Y., KONISHI, J., and BRECHBIEL, M.W. (2001). Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice. Clin. Cancer Res. 7, 3606-3612.
93. SAWAI, K., MAHATO, R.I., OKA, Y., TAKAKURA, Y., and HASHIDA, M. (1996). Disposition of oligonucleotides in isolated perfused rat kidney: Involvement of scavenger receptors in their renal uptake. J. Pharmacol. Exp. Ther. 279 284-290.
94. SHI, G., GUO, W., STEPHENSON, S.M., and LEE, R.J. (2002). Efficient intracellular drug and gene delivery using folate receptor-targeted pH-sensitive liposomes composed of cationic/anionic lipid combinations. J. Control. Release 80, 309-319.
95. SHUEY, D.J., McCALLUS, D.E., and GIORDANO, T. (2002) RNAi: Gene-silencing in therapeutic intervention. Drug Discov. Today 7, 1040-1046.
96. SOHAIL, M., and SOUTHERN, E.M. (2000). Selecting optimal antisense reagents. Adv. Drug Deliv. Rev. 44, 23-34.
97. SPITZER, S., and ECKSTEIN, F. (1988). Inhibition of deoxyribonucleases by phosphorothioate groups in oligodeoxyribonucleotides. Nucleic Acids Res. 16, 11691-11704.
98. SUDIMACK, J., and LEE, R.J. (2000). Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev. 41, 147-162.
99. SUGANO, M., and MAKINO, N. (1996). Changes in plasma lipoprotein cholesterol levels by antisense oligodeoxynucleotides against cholesteryl ester transfer protein in cholesterol-fed rabbits. J. Biol. Chem. 271, 19080-19083.
100. SUGANO, M., MAKINO, N., SAWADA, S., OTSUKA, S. WATANABE, M., OKAMOTO, H., KAMADA, M., and MIZUSHIMA, A. (1998). Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J. Biol. Chem. 273, 5033-5036.
101. TANAKA, M., and NYCE, J.W. (2001). Respirable antisense oligonucleotides: A new drug class for respiratory disease. Respir. Res. 2, 5-9.
102. TEMPLIN, M.V., LEVIN, A.A., GRAHAM, M.J., ABERG, P.M., AXELSSON, B.I., BUTLER, M., GEARY, R.S., and BENNETT, C.F. (2000). Pharmacokinetic and toxicity profile of a phosphorothioate oligonucleotide following inhalation delivery to lung in mice. Antisense Nucleic Acid Drug Dev. 10, 359-368.
103. TORTORA, G., BIANCO, R., DAMIANO, V., FONTANINI, G., DE PLACIDO, S., BIANCO, A.R., and CIARDIELLO, F. (2000). Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production. Clin. Cancer Res. 6, 2506-2512.
104. TORTORA, G., CAPUTO, R., DAMIANO, V., FONTANINI, G., MELISI, D., VENEZIANI, B.M., ZUNINO, F., BIANCO, A.R., and CIARDIELLO, F. (2001). Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. Clin. Cancer Res. 7, 4156-4163.
105. VASTAG, B. (2000). Folate gains momentum as a vehicle for drug delivery. J. Natl. Cancer Inst. 92, 1800-1801.
106. VERMA, S., and ECKSTEIN, F. (1998). Modified oligonucleotides: Synthesis and strategy for users. Annu. Rev. Biochem. 67, 99-134.
107. WAKITA, T., and WANDS, J.R. (1994). Specific inhibition of hepatitis C virus expression by antisense oligodeoxynucleotides. In vitro model for selection of target sequence. J. Biol. Chem. 269, 14205-14210.
108. WANG, H., CAI, Q., ZENG, X., YU, D., AGRAWAL, S., and ZHANG, R. (1999). Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration. Proc. Natl. Acad. Sci. USA 96(24), 13989-13994.
109. WANG, S., LEE, R.J., CAUCHON, G., GORENSTEIN, D.G., and LOW, P.S. (1995). Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc. Natl. Acad. Sci. USA 92, 3318-3322.
110. WARD, C.M. (2000). Folate-targeted non-viral DNA vectors for cancer gene therapy. Curr. Opin. Mol. Ther. 2, 182-187.
111. WEBB, M.S., and ZON, G. (1999). Preclinical and clinical experience of antisense therapy for solid tumors. Curr. Opin. Mol. Ther. 1, 458-463.
112. WESTLIN, W.F. (2001). Integrins as targets of angiogenesis inhibition. Cancer J. 7(Suppl 3), S139-S143.
113. WOOLF, T.M. (1998). Therapeutic repair of mutated nucleic acid sequences. Nat. Biotechnol. 16, 341-344.
114. WRAIGHT, C.J., and WHITE, P.J. (2001). Antisense oligonucleotides in cutaneous therapy. Pharmacol. Ther. 90, 89-104.
115. WU, G.Y., and WU, C.H. (1992). Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. J. Biol. Chem. 267, 12436-12439.
116. WU, J., NANTZ, M.H., and ZERN, M.A. (2002). Targeting hepatocytes for drug and gene delivery: Emerging novel approaches and applications. Front. Biosci. 7, d717-d725.
117. YU, R.Z., GEARY, R.S., LEEDS, J.M., WATANABE, T., MOORE, M., FITCHETT, J., MATSON, J., BURCKIN, T., TEMPLIN, M.V., and LEVIN, A.A. (2001a). Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey. J. Pharm. Sci. 90, 182-193.
118. YU, R.Z., ZHANG, H., GEARY, R.S., GRAHAM, M., MASARJIAN, L., LEMONIDIS, K., CROOKE, R., DEAN, N.M., and LEVIN, A.A. (2001b). Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice. J. Pharmacol. Exp. Ther. 296(2), 388-395.